Anticancer Research
Overview
Anticancer Research is a peer-reviewed scientific journal dedicated to advancing the understanding and treatment of cancer. It publishes original research articles, reviews, and clinical studies that explore various aspects of cancer biology, prevention, diagnosis, and therapy. With a focus on promoting innovative approaches and breakthrough discoveries, this journal serves as a valuable resource for researchers, clinicians, and healthcare professionals striving to combat cancer and improve patient outcomes.
Details
Details
Metrics
Metrics
h-index / Ranks: 1746
136
SJR / Ranks: 8032
562
CiteScore / Ranks: 6351
4.20
JIF / Ranks: 5186
2.0
Recent Articles
1.
Fujisawa T, Hojo H, Nakamura M, Makita K, Hirata H, Oyoshi H, et al.
Anticancer Res
. 2025 Mar;
45(3):1159-1169.
PMID: 40037892
Background/aim: Stereotactic body radiation therapy (SBRT) for centrally located hepatocellular carcinomas (HCCs) can cause severe central biliary toxicity. However, dose de-escalation SBRT has the potential to reduce biliary toxicity with...
2.
Hirata J, Hara T, Jimbo N, Ueki H, Okamura Y, Bando Y, et al.
Anticancer Res
. 2025 Mar;
45(3):1137-1147.
PMID: 40037891
Background/aim: This study aimed to investigate the genomic features of small cell neuroendocrine prostate cancer (SCPC) in Japanese patients, assess their relationships with platinum-based chemotherapy efficacy, and evaluate the potential...
3.
Tanabe N, Saeki I, Yamaoka K, Kawaoka T, Tomonari T, Tani J, et al.
Anticancer Res
. 2025 Mar;
45(3):1117-1125.
PMID: 40037890
Background/aim: Surgical resection remains the only curative treatment for combined hepatocellular-cholangiocarcinoma; however, systemic therapy is the primary treatment option for unresectable cases. This multicenter retrospective study aimed to assess the...
4.
Schomann-Finck M, Vogt T, Reichrath J
Anticancer Res
. 2025 Mar;
45(3):855-864.
PMID: 40037889
Cancer is a major public health problem and the second leading cause of mortality in the European Union. Vitamin D deficiency has been linked to cancer via several pathways. However,...
5.
Zupa A, Vita G, Omer L, Calice G, Conca R, Improta G
Anticancer Res
. 2025 Mar;
45(3):1015-1024.
PMID: 40037888
Background/aim: Approximately 80% of NRAS mutations in melanoma occur at codon 61, locking the NRAS protein into a GTP-bound state.We aimed to evaluate the mutant allele frequency (MAF) of as...
6.
Aoki Y, Han Q, Kubota Y, Masaki N, Tome Y, Bouvet M, et al.
Anticancer Res
. 2025 Mar;
45(3):929-934.
PMID: 40037887
Background/aim: Drug-resistance in osteosarcoma results in a very poor clinical prognosis and has been a recalcitrant problem over many decades. We have previously reported the development of super methotrexate (MTX)-resistant...
7.
Hsu J, Ou H, Ou Y, Lin Y, Huang L, Weng W, et al.
Anticancer Res
. 2025 Mar;
45(3):1281-1289.
PMID: 40037886
Background/aim: This study aimed to assess the safety and outcomes of intraoperative ventriculoperitoneal (VP) shunt clamping during robotic-assisted radical prostatectomy (RaRP) in patients with VP shunts. Patients And Methods: A...
8.
Prognostic Relationship Between the Cachexia Index and Osteopenia in Patients With Pancreatic Cancer
Sakamoto T, Kishino M, Murakami Y, Miyatani K, Shishido Y, Kihara K, et al.
Anticancer Res
. 2025 Mar;
45(3):1225-1231.
PMID: 40037885
Background/aim: The cachexia index (CXI) is a novel biomarker for cancer cachexia. Osteopenia is defined as low bone mineral density (BMD), which is closely associated with cancer cachexia. Osteopenia has...
9.
Wu Y, Ku M, Huang W, Dias L, Chen C
Anticancer Res
. 2025 Mar;
45(3):825-842.
PMID: 40037884
Nuclear enriched abundant transcript 1 (NEAT1), a long non-coding RNA (lncRNA), is a critical player in the pathogenesis and progression of ovarian cancer. Its abnormal expression in patients' follicular fluid...
10.
Kumaria A, Ashkan K
Anticancer Res
. 2025 Mar;
45(3):1301-1303.
PMID: 40037883
No abstract available.